In hepatitis B virus-induced hepatocellular carcinoma, the level of ATG5-ATG12 conjugation is promoted, and ATG12 silencing can moderately increase apoptotic rates of liver cancer cells [48]. It can be seen that they are both potential drug targets for cancer treatments. Here, ATG5 is linked to cancer.